CEO Dr. Pnina Fishman
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), (TASE: CFBI), CEO Dr. Pnina Fishman will ring The Opening Bell at the New York Stock Exchange (NYSE), on Thursday, December 5, 2013, at 09:30 a.m to commemorate Can-Fite’s recent listing on the NYSE MKT. Members of Can-Fite’s management and guests will join Dr. Fishman.
“This ceremony is a tribute to our executive management team and our partners who have demonstrated their continued confidence in our product pipeline, ” says Dr. Fishman. “We are honored that the NYSE has invited our company to ring The Opening Bell. This is particularly an exciting time for us as our portfolio of indications is approaching into more advanced stages of clinical development and we soon expect to announce the results of our Phase IIb rheumatoid arthritis and Phase III dry eye syndrome studies.”
Can-Fite recently announced the listing of its Level II American Depository Receipts (“ADRs”) onto the NYSE MKT and began trading on November 19, 2013.
Can-Fite , an Israeli public company which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys in Israel.